2-乙氧基-4-甲氧基苯甲醛 | 42924-37-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-乙氧基-4-甲氧基苯甲醛
• 英文名称: 2-ethoxy-4-methoxybenzaldehyde
• 英文别名: 2-Aethoxy-4-methoxy-benzaldehyd
• CAS: 42924-37-8
• 化学式: C₁₀H₁₂O₃
• 分子量: 180.203
• InChiKey: QXAVANUCHWRYFF-UHFFFAOYSA-N

物化性质

• 沸点：
  310.8±22.0 °C(Predicted)
• 密度：
  1.088±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-乙氧基-4-甲氧基苯甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以85%的产率得到2-ethoxy-4-methoxybenzyl alcohol
  参考文献：
  名称：

  烟酰胺衍生物作为一种新型的胃H + / K（+）-ATPase抑制剂。1.N-取代的2-（苯甲酰基-和苄基亚磺酰基）烟酰胺的合成和结构-活性关系。

  摘要：

  合成了一系列新的N-取代的2-（苯甲酰基-和苄基亚磺酰基）烟酰胺7和8。在顶细胞的酸性环境中进行酸活化后，这些化合物会转化为活性形式2,3,2-二氢-3-氧代异噻唑并[5,4-b]吡啶5，从而抑制胃H + / K（+）- ATP酶。评价了由丁二酰cAMP刺激的离体兔壁细胞在体外对[14C]氨基比林积累的抑制活性，以及​​体内十二指肠内给药对幽门结扎的大鼠中组胺诱导的胃酸分泌的影响，并研究了其构效关系。在合成的化合物中，2-[（（2,4-二甲氧基苄基）亚磺酰基] -N-（4-吡啶基）烟酰胺（8b）在体内和体外表现出与奥美拉唑相同的有效抑制活性，而奥美拉唑是典型的H + / K（ +）-ATPase抑制剂。此外，8b在中性和弱酸性pH下比奥美拉唑，兰索拉唑和pan托拉唑更稳定。化合物8b被认为是治疗与酸有关的胃肠道疾病的有前途的药物。

  DOI：

  10.1021/jm9605593
• 作为产物：
  描述：

  3-甲氧基苯酚 在 盐酸 、 sodium ethanolate 作用下， 生成 2-乙氧基-4-甲氧基苯甲醛
  参考文献：
  名称：

  Sonn; Patschke, Chemische Berichte, 1925, vol. 58, p. 1702

  摘要：

  DOI：

文献信息

• Design, Synthesis of Some Novel Thiazolidin-4-one Derivatives Bearing Benzimidazole Nucleus and Biological Evaluation of their Possible in vitro Antiinflammatory as Cyclooxygenase Inhibitors and Antioxidant Activity
  作者：U. Sahoo、A.K. Seth、R. Balaraman、R. Velmurugan

  DOI：10.14233/ajchem.2015.17788

  日期：——

  A series of 2-[2-(4-cyanophenyl)-6-substituted-1H-benzimidazol-1-yl]-N-[2-(substituted)-4-oxo-1,3- thiazolidin-3-yl]acetamide [9(I-XXXI)] were synthesized. Substituted o-phenylenediamine was reacted with substituted 4-cyanobenzaldehydes in the presence of sodium metabisulfite to furnish substituted 2-(4-cyanophenyl)-1H-benzimidazoles (1). When these substituted 2-(4-cyanophenyl)-1H-benzimidazoles were further treated with ethyl chloroacetate in KOH/DMSO, N-alkylated product (2-(4-cyanophenyl)-benzimidazol-1-yl)-acetic acid ethyl esters (2) was formed. To synthesize 2-(4-cyanophenyl)-benzimidazol-1-yl-acetic acid hydrazides (3) chemical reactions were conducted between hydrazine hydrate and the esters (2). When a mixture of 2-(4-cyanophenyl)-benzimidazol-1-yl)-acetic acid hydrazide (3) react with substituted aldehydes in ethanol was reflux, imines intermediates [4(I-XXXI)] was formed. To synthesize 9(I-XXXI) reactions were occurred between a mixture of imine intermediate and thioglycollic acid in dioxane. The structures of newly synthesized compounds 9(I-XXXI) was confirmed by spectroscopic techniques. All the synthesized compounds were screened for its in vitro antioxidant and antiinflammatory activity. The in vitro antioxidant and antiinflammatory activity might be attributed due to the presence of more electrons withdrawing group and moiety having more lipophilicity also more electronegativity in nature.

  合成了一系列 2-[2-(4-氰基苯基)-6-取代-1H-苯并咪唑-1-基]-N-[2-(取代)-4-氧代-1,3-噻唑啉-3-基]乙酰胺[9(I-XXXI)]。在焦亚硫酸钠存在下，取代的邻苯二胺与取代的 4-氰基苯甲醛反应，生成取代的 2-(4-氰基苯基)-1H-苯并咪唑 (1)。当这些取代的 2-(4-氰基苯基)-1H-苯并咪唑在 KOH/DMSO 中与氯乙酸乙酯进一步处理时，生成了 N-烷基化产物（2-(4-氰基苯基)-苯并咪唑-1-基）-乙酸乙酯（2）。为了合成 2-(4-氰基苯基)-苯并咪唑-1-基乙酸肼（3），水合肼与酯（2）发生了化学反应。当 2-(4-氰基苯基)-苯并咪唑-1-基)-乙酸酰肼(3)与取代醛的混合物在乙醇中回流反应时，生成亚胺中间体[4(I-XXXI)]。为了合成 9(I-XXXI)，亚胺中间体和硫代乙醇酸的混合物在二噁烷中发生了反应。新合成的化合物 9(I-XXXI) 的结构通过光谱技术得到了确认。对所有合成化合物进行了体外抗氧化和抗炎活性筛选。体外抗氧化和抗炎活性可能是由于存在更多的退电子基团和亲油性更强、电负性更强的分子。
• [EN] AGONISTS OF FOLLICLE STIMULATING HORMONE ACTIVITY<br/>[FR] AGONISTE D'ACTIVITE HORMONALE STIMULANT UN FOLLICULE
  申请人：AFFYMAX RES INST

  公开号：WO2002009706A1

  公开（公告）日：2002-02-07

  In one aspect, the present invention provides novel compounds. In addition, the invention provides a FSH receptor agonist, wherein the agonist binds to a FSH receptor having a FSH binding site and, wherein the agonist is noncompetitve with FSH for the FSH binding site. In another aspect, the invention provides methods of using the compounds of the present invention for diverse pharmaceutical applications including, for example, CNS antiischemic agents, agents with antipsychotic or other psychoactive properties, antimicrobial agents and mammalian fertility regulating agent.

  在一个方面，本发明提供了新型化合物。此外，本发明提供了FSH受体激动剂，其中该激动剂结合到具有FSH结合位点的FSH受体上，且该激动剂在FSH结合位点上与FSH非竞争性地结合。在另一个方面，本发明提供了使用本发明化合物进行各种药物应用的方法，包括例如CNS抗缺血剂、具有抗精神病或其他精神活性特性的剂、抗微生物剂和哺乳动物生育调节剂。
• Pyrimidine and quinazoline derivatives
  申请人：Christ Andreas D.

  公开号：US20080045550A1

  公开（公告）日：2008-02-21

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物，其中A，R1到R5和G的定义如描述和权利要求中所述，并且其药学上可接受的盐。本发明还涉及含有这些化合物的制药组合物，以及其制备过程和用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Therapeutic Compounds 570
  申请人：Bayrakdarian Malken

  公开号：US20090099195A1

  公开（公告）日：2009-04-16

  Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 , R 3 , R 4 , and R 5 and are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  公式I的化合物或其药学上可接受的盐：其中R1、R2、R3、R4和R5如规范中所定义，以及制备包括这些化合物的盐和药物组合物。它们在治疗中有用，特别是在疼痛管理方面。
• Pyrimidine and Quinazoline Derivatives
  申请人：Christ Andreas D.

  公开号：US20100069413A1

  公开（公告）日：2010-03-18

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及公式中的化合物，其中A、R1至R5和G如描述和权利要求中所定义，并且其药学上可接受的盐。本发明还涉及含有这些化合物的药物组合物，以及制备它们的过程和它们用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。